Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Pseudomonas aeruginosa is one of the major causative microorganisms of ventilator-associated pneumonia often resistant to antibiotics. In experimental models, nebulization of antibiotics delivers high lung tissue concentrations of antibiotics in infected lungs and increases lung bacterial killing. The aim of the study is to assess the efficiency of nebulized ceftazidime and amikacin in the treatment of pneumonia caused by Pseudomonas aeruginosa in ventilated patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Groupe Hospitalier Pitie-Salpetriere
• Treatments: Amikacin; Ceftazidime

Criteria

Inclusion Criteria:

• Male or female >18 years old, ventilator associated pneumonia caused by pseudomonas aeruginosa

• Written informed consent provided by the relatives

Exclusion Criteria:

• Pseudomonas aeruginosa resistant to ceftazidime and amikacin

• Pseudomonas aeruginosa pneumonia associated with other infections requiring intravenous treatment

• Severe septic shock and severe hypoxemia

• Allergy to ceftazidime or amikacin